Champions Oncology

Champions Oncology is a CRO specializing in oncology with over 1400 patient-derived cancer models. Champions Oncology conducts contract non-clinical studies using proprietary models for everything from early-stage drug discovery to immuno-oncology. This section summarizes the features of the company's contract non-clinical study services, its disease models, and examples of non-clinical studies.

Features of Champions Oncology's Contract Non-clinical Trial Services

Unique workflow dedicated to early drug discovery services

The company specializes in two types of early drug discovery services to provide highly reliable data and cost-effective solutions quicklyProvides a uniquely integrated workflowThe company's two main products are "ChemiSelect" and "ADC-Flow". ChemiSelect" is a platform developed to effectively identify and prioritize chemotypes, while "ADC-Flow" is a platform for screening and designing efficient antibody-drug conjugates (ADCs) for client targets.

Various evaluations can be performed in mouse clinical trials

The company's Mouse Clinical Trials (MCTs) can use patient-derived cancer models implanted in immunocompromised mice to evaluate efficacy against a variety of tumor types and to investigate resistance mechanisms and optimize drug combinations.

Also, the company's MCT design is,Customized to the client's research objectivesWe can do this. Therefore, from model design to study design and final analysis, the company's experts will work with the client to ensure that the study meets its objectives.

Provides a humanized mouse tumor model

The company offersProviding humanized mouse tumor models specific to human immune targetsto support preclinical immuno-oncology research. The platform enables the evaluation of the efficacy and mechanism of action of a wide variety of cancer drugs that modulate human immunity, including checkpoint inhibitors, monoclonal and bispecific antibodies, cancer vaccines, cytokine therapies, and combination therapies.

An example of Champions Oncology's disease model

The company covered molecular and pathologic diversity across major cancer types,Over 1,400 PDX models in our portfolioThe results of this study are shown in Figure 1. These models have been established from biopsy tissue taken from patients with advanced cancer and pretreated with novel therapies. The pretreated PDX models are highly clinically relevant in elucidating resistance mechanisms in cancers that have progressed after standard therapy and in the search for new targets and therapeutic strategies.

Champions Oncology's Non-clinical Case Studies

A case study of the use of the PDX model bank for prostate cancer

Amgen to evaluate AMG160, a PSMA-targeted BiTE molecule with a long half-life,Leveraging Champions Oncology's Prostate Cancer PDX Model BankThe patient was treated with AMG160. In this case, AMG160 is being evaluated in combination with other immunotherapies that reactivate the immune system.

Champions Oncology Company Information

Champions Oncology is a provider of advanced technologies and products for the development and patient-tailored use of oncology drugs. In particular, the company utilizes patient-derived tumor models to provide personalized services to pharmaceutical and biotech companies.